AU8764398A - N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators - Google Patents
N6-substituted-adenosine-5'-uronamides as adenosine receptor modulatorsInfo
- Publication number
- AU8764398A AU8764398A AU87643/98A AU8764398A AU8764398A AU 8764398 A AU8764398 A AU 8764398A AU 87643/98 A AU87643/98 A AU 87643/98A AU 8764398 A AU8764398 A AU 8764398A AU 8764398 A AU8764398 A AU 8764398A
- Authority
- AU
- Australia
- Prior art keywords
- adenosine
- uronamides
- substituted
- receptor modulators
- adenosine receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5406497P | 1997-07-29 | 1997-07-29 | |
US60054064 | 1997-07-29 | ||
PCT/US1998/016053 WO1999006053A1 (en) | 1997-07-29 | 1998-07-29 | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
AU8764398A true AU8764398A (en) | 1999-02-22 |
Family
ID=21988552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU87643/98A Abandoned AU8764398A (en) | 1997-07-29 | 1998-07-29 | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1019427A4 (en) |
JP (1) | JP2003517423A (en) |
AU (1) | AU8764398A (en) |
CA (1) | CA2296485A1 (en) |
WO (1) | WO1999006053A1 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2289731A1 (en) * | 1997-05-09 | 1998-11-12 | The United States Of America, Represented By The Secretary, Department O F Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
CZ302486B6 (en) | 1998-06-02 | 2011-06-15 | Osi Pharmaceuticals, Inc. | N-6-Substituted-7-deazapurine, process for its preparation and pharmaceutical composition containing thereof |
IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
KR100840727B1 (en) | 1999-12-02 | 2008-06-23 | 오에스아이 파마슈티컬스, 인코포레이티드 | Compounds specific to adenosine £á1, £á2£á and £á3 receptor and uses thereof |
US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
WO2002035231A1 (en) * | 2000-10-26 | 2002-05-02 | Actar Ab | Screening method using a g coupled receptor associated with a specific g protein |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
JP4012070B2 (en) * | 2001-01-16 | 2007-11-21 | カン−フィテ・バイオファーマ・リミテッド | Use of an adenosine A3 receptor agonist to inhibit viral replication |
US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
EP1450811B1 (en) | 2001-11-30 | 2009-10-21 | OSI Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
EA011809B1 (en) | 2001-12-20 | 2009-06-30 | Оси Фармасьютикалз, Инк. | Pyrimidine a2b selective antagonists compounds, their synthesis and use |
CN1816551A (en) | 2001-12-20 | 2006-08-09 | Osi药物公司 | Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
EP1685135B1 (en) * | 2003-10-21 | 2010-05-26 | Inspire Pharmaceuticals, Inc. | TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION |
US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
EP1778239B1 (en) * | 2004-07-28 | 2013-08-21 | Can-Fite Biopharma Ltd. | Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome |
EP1798233A1 (en) * | 2005-12-19 | 2007-06-20 | Faust Pharmaceuticals | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof |
EP2227234B1 (en) | 2007-10-15 | 2014-05-07 | Can-Fite Biopharma Ltd. | Method for inducing hepatocyte proliferation and uses thereof |
CN102427819A (en) | 2009-05-17 | 2012-04-25 | 坎-菲特生物药物有限公司 | A3 adenosine receptor agonists for the reduction of intraocular pressure |
EP2456419B1 (en) | 2009-07-21 | 2016-11-23 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
EP2542242A1 (en) | 2010-03-03 | 2013-01-09 | The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | A3ar agonists for the treatment of uveitis |
EP2892533A1 (en) | 2012-08-09 | 2015-07-15 | Can-Fite Biopharma Ltd. | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction |
IL242723B (en) | 2015-11-23 | 2019-12-31 | Can Fite Biopharma Ltd | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
IL254535A0 (en) | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | A3 adenosine receptor ligand for managing cytokine release syndrome |
IL264112A (en) | 2019-01-06 | 2020-07-30 | Fishman Pnina | An a3 adenosine receptor ligand for use for reducing level of adipocytes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5310731A (en) * | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
CA2289731A1 (en) * | 1997-05-09 | 1998-11-12 | The United States Of America, Represented By The Secretary, Department O F Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
-
1998
- 1998-07-29 JP JP2000504866A patent/JP2003517423A/en active Pending
- 1998-07-29 WO PCT/US1998/016053 patent/WO1999006053A1/en not_active Application Discontinuation
- 1998-07-29 CA CA002296485A patent/CA2296485A1/en not_active Abandoned
- 1998-07-29 EP EP98939156A patent/EP1019427A4/en not_active Withdrawn
- 1998-07-29 AU AU87643/98A patent/AU8764398A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1019427A1 (en) | 2000-07-19 |
EP1019427A4 (en) | 2000-07-19 |
WO1999006053A1 (en) | 1999-02-11 |
CA2296485A1 (en) | 1999-02-11 |
JP2003517423A (en) | 2003-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU8764398A (en) | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators | |
GB2353527B (en) | Adenosine A3 receptor modulators | |
AU7649196A (en) | Ink compositions | |
AU3110095A (en) | Glutamate receptor | |
AU7606198A (en) | Coloring composition | |
AU5335798A (en) | Stomatic composition | |
AU7132898A (en) | Edg-1-like receptor | |
AU8747498A (en) | Food-preservative composition | |
AU9066598A (en) | Substituted 4-benzoyl-pyrazoles | |
AU6748196A (en) | Receptor | |
AU8182098A (en) | Parkinson's disease tests | |
AU1535699A (en) | Novel receptors opg-2 | |
AU8121998A (en) | Composition | |
AUPO938697A0 (en) | Novel receptor | |
AU6035398A (en) | Human c5a-like receptor | |
AU1098499A (en) | Emulsifier-lipid composition | |
AU6090898A (en) | Substituted 4-benzoyl-pyrazoles | |
AU9676498A (en) | Bilaterally connectable softshell reservoir | |
AU4345896A (en) | Novel receptor | |
AU9659498A (en) | Distribution means | |
AU7530198A (en) | Substituted 4-benzoyl-pyrazoles | |
AU7212698A (en) | Substituted aryluracils | |
CA2209198A1 (en) | Adjustable platform | |
AUPO910797A0 (en) | Receptor | |
AUPP062097A0 (en) | Novel receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |